Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed outlook. The company's financial performance and product development show promise with ongoing trials and potential applications in multiple indications. However, there are uncertainties regarding trial outcomes and management's reluctance to provide clear guidance on certain metrics. The Q&A section reveals some positive analyst sentiment but also highlights risks and unclear management responses. The lack of guidance and need for additional funding are concerns. Overall, the stock price reaction is expected to be neutral in the short term, as the positive aspects are balanced by uncertainties and financial challenges.
Key Financial Performance
Research and Development Expenses $8.5 million in Q3 2025, compared to $5.2 million in Q3 2024, a $3.3 million increase primarily due to higher clinical trial and manufacturing costs for soquelitinib and increased personnel-related costs.
Net Loss $10.2 million in Q3 2025, compared to $40.2 million in Q3 2024. The decrease was mainly due to a $32.8 million noncash loss in Q3 2024 related to the change in fair value of Corvus' warrant liability, which was not present in Q3 2025.
Noncash Loss Related to Angel Pharmaceuticals $300,000 in Q3 2025, compared to $700,000 in Q3 2024, reflecting a decrease in this specific noncash loss.
Stock Compensation Expense $1.2 million in Q3 2025, compared to $700,000 in Q3 2024, an increase due to higher personnel-related costs.
Cash, Cash Equivalents, and Marketable Securities $65.7 million as of September 30, 2025, compared to $52 million as of December 31, 2024, reflecting an increase in available funds.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Soquelitinib development: Focus on atopic dermatitis and T cell lymphomas. Completed enrollment in extension Cohort 4 of Phase I trial, with results expected in January. Phase II trial for atopic dermatitis to begin in early Q1 2026.
Phase I trial results: Cohort 3 showed a mean percent reduction of EASI score of 64.8% at day 28, with 50% achieving EASI 75. Extension Cohort 4 aims to confirm results and explore longer treatment duration.
Phase II trial design: Randomized, placebo-controlled, double-blinded trial with 200 patients. Focus on moderate to severe atopic dermatitis patients who failed prior therapies. Primary endpoint: mean percent reduction in EASI score at week 12.
Market positioning for soquelitinib: Positioned as an oral medication with a novel mechanism of action for atopic dermatitis and T cell lymphomas. Targeting patients who failed prior systemic therapies, including Dupixent or JAK inhibitors.
Financials: R&D expenses increased to $8.5M in Q3 2025 due to clinical trial and manufacturing costs. Net loss reduced to $10.2M from $40.2M in Q3 2024. Cash reserves at $65.7M, expected to fund operations into Q4 2026.
Leadership updates: David Moore appointed to Board of Directors, bringing expertise in strategy, commercial, and market access from Novo Nordisk.
Strategic focus: Expanding ITK inhibitor platform beyond atopic dermatitis to other immune diseases. Building momentum with ongoing trials and upcoming data presentations.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Increased R&D Expenses: Research and development expenses increased significantly from $5.2 million in Q3 2024 to $8.5 million in Q3 2025, primarily due to higher clinical trial and manufacturing costs, as well as increased personnel-related costs. This could strain financial resources and impact operational flexibility.
Net Loss: The company reported a net loss of $10.2 million in Q3 2025, which, while lower than the $40.2 million loss in Q3 2024, still represents a significant financial challenge. Sustained losses could impact the company's ability to fund future operations and strategic initiatives.
Dependence on Soquelitinib: The company's future success heavily relies on the development and approval of soquelitinib for atopic dermatitis and T cell lymphomas. Any delays or failures in clinical trials or regulatory approvals could severely impact the company's strategic objectives.
Regulatory and Clinical Risks: The company faces risks related to the initiation and completion of clinical trials, including the planned Phase II trial for atopic dermatitis and the ongoing Phase III trial for PTCL. Regulatory hurdles or adverse trial outcomes could delay or derail these programs.
Market Competition: The company acknowledges increasing interest in drugs with novel mechanisms for atopic dermatitis and other inflammatory diseases. Competitive pressures from other pharmaceutical companies could impact market share and revenue potential.
Cash Flow and Funding: Although the company has $65.7 million in cash and marketable securities, it only expects to fund operations into Q4 2026. This limited runway may necessitate additional funding, which could dilute existing shareholders or increase financial risk.
Strategic Execution Risks: The company is expanding its focus to include a broad range of immune diseases beyond atopic dermatitis. This diversification could stretch resources and divert attention from core programs, increasing execution risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Upcoming Data Release for Soquelitinib: The company plans to report the full data set from the extension Cohort 4 of the Phase I trial in January 2026. This data will evaluate the efficacy of an 8-week treatment duration for atopic dermatitis.
Phase II Trial for Atopic Dermatitis: The initiation of a Phase II trial for soquelitinib in atopic dermatitis is scheduled for early Q1 2026. The trial will involve approximately 200 patients globally, testing various dosages over a 12-week treatment period.
Phase III Trial for Peripheral T Cell Lymphoma (PTCL): Enrollment is ongoing for the registrational Phase III trial of soquelitinib in relapsed PTCL, with interim data expected in late 2026.
ASH Presentation: Final results from the Phase I/Ib trial of soquelitinib for relapsed/refractory T cell lymphomas will be presented at the American Society of Hematology (ASH) meeting in December 2025. This will include clinical data and preclinical work supporting its use in T cell lymphoma and immune-mediated diseases.
Future Applications of ITK Inhibition: The company is exploring the potential of ITK inhibition in a broad range of indications, including dermatology, rheumatology, pulmonary medicine, solid cancers, and other diseases.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Can you provide context on the comparability and enthusiasm for soquelitinib in peripheral T cell lymphoma based on the ASH abstract?
A:The PFS and OS data presented at the ASH meeting are impressive, especially for a Phase I trial in a disease with a median survival of about 6 months in relapsed cases. The trial has provided insights into immunobiology, safety, pharmacokinetics, and mechanisms of action. Responses in GATA3-positive T cell lymphomas, which are relevant to immune diseases like atopic dermatitis, further support the drug's novel mechanism of action and safety profile.
Q:Will the expanded treatment duration and number of patients in the atopic dermatitis trial improve efficacy?
A:The expanded cohort aims to confirm consistency with previous data and evaluate whether extending treatment beyond 28 days improves results. The goal is to confirm safety and efficacy while showing consistency in a larger patient set.
Q:What are the plans for advancing soquelitinib in other indications?
A:Soquelitinib is being studied in a Phase III trial for peripheral T cell lymphoma, a Phase II trial for atopic dermatitis, and a trial for lymphoproliferative disease (ALPS). Preclinical models suggest potential in asthma, psoriasis, scleroderma, and systemic sclerosis. Plans for other immune-related diseases, such as asthma and another dermatologic condition, will be discussed early next year.
Q:What are the next steps for the ciforadenant trial in renal cell carcinoma?
A:The trial, conducted with the Kidney Cancer Consortium, is ongoing with 19 out of 50 patients still on treatment or follow-up. The company will decide on further steps based on the evolving data.
Q:Are the baseline characteristics of Cohort 4 similar to prior cohorts in the atopic dermatitis trial?
A:Yes, the baseline characteristics of Cohort 4 are very similar to Cohort 3. The trial uses the same 17 U.S. centers, and eligibility criteria have not changed.
Q:What should be the bar for the EASI score in the Phase II atopic dermatitis trial?
A:The bar for the EASI score is not yet defined, as the trial includes patients who failed JAK inhibitors and Dupi. The company aims to evaluate the drug's efficacy in this unique patient population and expand its potential use.
Q:What are the plans for other dermatologic indications and running multiple trials simultaneously?
A:The company is considering indications like hidradenitis suppurativa, prurigo nodularis, and alopecia areata. They plan to run multiple trials in immune diseases, including dermatology, pulmonary medicine, oncology, and rheumatology, but will need to raise funds to support these activities.
Q:What are the timelines and commercial opportunities for soquelitinib in peripheral T cell lymphoma?
A:The Phase III trial has a futility interim analysis planned for the end of 2026, with full data by the end of 2027. The trial is relatively small (150 patients) with short endpoints, and the drug could be used immediately in all T cell lymphomas if approved, as there is no competition in this area.
Q:Will there be post hoc analysis and biomarker studies for Cohort 4 in the atopic dermatitis trial?
A:Yes, post hoc analysis will evaluate efficacy in Dupi and JAK-naive and refractory populations. Biomarker studies will include single-cell RNA sequencing of blood to identify new biomarkers for these heterogeneous diseases.
Q:Why is the Phase II atopic dermatitis trial using a 12-week treatment duration?
A:The 12-week duration is based on data showing most efficacy is achieved within this timeframe. The company aims to maximize responses while minimizing treatment duration.
Q:Are there plans for partnerships or licensing deals for soquelitinib?
A:The company is in discussions with major companies about ITK as a target and will evaluate partnering opportunities. They also plan to raise funds to develop their programs further.
Q:What is the strategy for advancing next-generation ITK inhibitors versus soquelitinib?
A:The company is prioritizing soquelitinib, which has extensive safety and efficacy data, but is also exploring next-generation ITK degraders and other formulations. Advancing soquelitinib will be faster than developing new compounds.
Q:Will the Phase II atopic dermatitis trial be powered for subgroup analysis of Dupi and JAK-exposed patients?
A:The trial will stratify patients based on prior systemic therapy exposure but will not be powered specifically for subgroup analysis. The focus is on including all patients and achieving a positive study outcome.
Q:Review of Unclear Management Responses
A:Management avoided providing a clear bar for the EASI score in the Phase II atopic dermatitis trial, citing a lack of published data on drug responses in patients who failed JAK inhibitors or Dupi. They also did not commit to powering the trial for subgroup analysis of Dupi and JAK-exposed patients, stating insufficient information to make such a commitment.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Angel Pharmaceuticals
CEO Chairman
Chemistry Inc
China loss
Co Founder
Conference Instructions
Conference result
Corvus Pharmaceuticals
Financial Results
Form Real
Founder President
Inc afternoon
Instructions pleasure
Kubow Real
Officer Senior
Pharmaceutical Sciences
Pharmaceuticals Update
President CEO
Real Chemistry
Results Conference
Update Financial
afternoon Corvus
cash progress
law overview
liability noncash
loss Angel
loss change
loss noncash
noncash loss
period filing
personnel loss
plan Co
pleasure Kubow
security cash
sir comment
CRVS Transcript
Corvus Pharmaceuticals, Inc. (CRVS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-8
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call summary presents a mixed picture. Basic financial performance shows increased net loss and stock compensation, but cash reserves have grown. Product development updates are promising, with multiple trials underway. Market strategy lacks clarity due to abstract rejection and unclear trial plans. Financial health is stable, with increased cash reserves. Shareholder return plans are not mentioned. Q&A reveals potential trial delays and management's lack of clarity on certain issues, balancing positive trial progress. Overall, the sentiment is neutral due to balanced positives and negatives, and the lack of market cap information limits the prediction's precision.
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2025 Earnings Call Transcript
Unknown11-4
The earnings call summary presents a mixed outlook. The company's financial performance and product development show promise with ongoing trials and potential applications in multiple indications. However, there are uncertainties regarding trial outcomes and management's reluctance to provide clear guidance on certain metrics. The Q&A section reveals some positive analyst sentiment but also highlights risks and unclear management responses. The lack of guidance and need for additional funding are concerns. Overall, the stock price reaction is expected to be neutral in the short term, as the positive aspects are balanced by uncertainties and financial challenges.
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2025 Earnings Call Transcript
Unknown8-8
The earnings call presents a mixed outlook. Financial performance shows increased R&D expenses and a net loss, but cash reserves are sufficient until late 2026. Product development is progressing, with Phase II trials on track and partnerships supporting expansion. However, the reliance on soquelitinib and competitive pressures pose risks. The Q&A highlights strategic focus but lacks clarity on some future plans. Overall, the sentiment is neutral, with no strong catalysts for significant stock movement in either direction.
CRVS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
